Journal of the Neurological Sciences
Volume 200, Issue 1 , Pages 1-10 , 15 August 2002

The nature of the autonomic dysfunction in multiple system atrophy

Received 26 November 2001 ,Revised 29 March 2002 ,Accepted 29 April 2002.

References 

  1. Bannister R, Mathias CJ. Clinical features and investigations of the primary autonomic failure syndromes. In:  Bannister R,  Mathias CJ editor. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Oxford: Oxford Univ. Press; 1992;p. 531–547
  2. Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy. Neurology. 1997;48:384–393
  3. Polinsky RJ. Shy-Drager syndrome and multiple system atrophy. In:  Robertson D,  Biagioni I editor. Disorders of the Autonomic Nervous System. Australia: Harwood Academic Publishers; 1995;p. 107–139
  4. Polinsky RJ, Nee LE. Autonomic failure: nosology, clinical evolution, and prognosis. Ann. Neurol. 1989;26:121
  5. Wallin BG, Sundlof G, Eriksson BM, et al.  Plasma noradrenaline correlates to sympathetic muscle nerve activity in normotensive man. Acta Physiol. Scand. 1981;111:69–73
  6. Polinsky RJ, Kopin IJ, Ebert MH, et al.  Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology. 1981;31:1–7
  7. Ziegler MG, Lake CR, Kopin IJ. The sympathetic-nervous-system defect in primary orthostatic hypotension. N. Engl. J. Med. 1977;296:293–297
  8. Polinsky RJ, Goldstein DS, Brown RT, et al.  Decreased sympathetic neuronal uptake in idiopathic orthostatic hypotension. Ann. Neurol. 1985;18:48–53
  9. Kopin IJ, Polinsky RJ, Oliver JA, et al.  Urinary catecholamine metabolites distinguish different types of sympathetic neurol dysfunction in patients with orthostatic hypotension. J. Clin. Endocrinol. Metab. 1983;57:632–637
  10. Polinsky RJ, Brown RT, Curras MT, et al.  Central and peripheral effects of arecoline in patients with autonomic failure. J. Neurol. Neurosurg. Psychiatry. 1991;54:807–812
  11. Polinsky RJ, Taylor IL, Chew P, et al.  Pancreatic polypepetide responses to hypoglycemia in chronic autonomic failure. J. Clin. Endocrinol. Metab. 1982;54:48–52
  12. Polinsky RJ, Taylor IL, Weise V, Kopin IJ. Gastrin responses in patients with adrenergic insufficiency. J. Neurol. Neurosurg. Psychiatry. 1988;51:67–71
  13. Polinsky RJ. Neuropharmacological investigation of autonomic failure. In:  Bannister S,  Mathias CJ editor. Autonomic Failure: A Textbook of Clinical Disorders of the autonomic Nervous System. Oxford: Oxford Univ. Press; 1992;p. 334–358
  14. Kennedy PG, Duchen LW. A quantitative study of intermediolateral column cells in motor neuron disease and the Shy-Drager syndrome. J. Neurol. Neurosurg. Psychiatry. 1985;48:1103–1106
  15. Oppenheimer D. Lateral horn cells in progressive autonomic failure. L. Neurol. Sci. 1980;46:393–404
  16. Wenning GK, Tison F, Ben-Shlomo Y, et al.  Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord. 1997;12:133–147
  17. Gray F, Vincent D, Hauw JJ. Quantitative study of lateral horn cells in 15 cases of multiple system atrophy. Acta Neuropathol. 1988;75:513–518 Berlin
  18. Low PA. Quantitation of autonomic function. In:  Dyck PJ,  Thomas PK,  Lambert EH,  Bunge R editor. Peripheral Neuropathy. Philadelphia: Saunders; 1984;p. 1139–1166
  19. Sung JH, Mastri AR, Segal E. Pathology of Shy-Drager syndrome. J. Neuropathol. Exp. Neurol. 1979;38:353–368
  20. Konno H, Yamamoto T, Iwasaki Y, Iisuka H. Shy-Drager syndrome and amyotropic lateral sclerosis: cytoarchitectonic and morphometric studies of sacral autonomic neurons. J. Neurol. Sci. 1986;73:193–204
  21. Daniel SE. The neuropathology and neurochemistry of multiple system atrophy. In:  Bannister R,  Mathias C editor. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Oxford: Oxford Univ. Press; 1992;p. 564–585
  22. Matthews MR. Autonomic ganglia in multiple system atrophy and pure autonomic failure. In:  Bannister R,  Mathias CJ editor. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Oxford: Oxford Univ. Press; 1992;p. 593–621
  23. Kontos HA, Richardson DW, Norvell JE. Norepinephrine depletion in idiopathic orthostatic hypotension. Ann. Int. Med. 1975;82:336–341
  24. Rubenstein AE, Yahr MD, Mytilineou C. Peripheral adrenergic hypersensitivity in orthostatic hypotension: the effects of denervation versus decentralization. Neurology. 1978;28:376; Minneapolis
  25. Nanda RN, Boyle RC, Gillespie JS, et al.  Adrenergic innervation of peripheral blood vessels in patients with neurogenic orthostatic hypotension. J. Neuropathol. Appl. Neurobiol. 1976;2:49
  26. Bannister R, Crowe R, Eames R, Burnstock G. Adrenergic innervation in autonomic failure. Neurology. 1981;31:1501–1506
  27. De Volder AG, Francart J, Laterre C, et al.  Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann. Neurol. 1989;26:239–247
  28. Fulham MJ, Dubinsky RM, Polinsky RJ, et al.  Assessment of multiple system atrophy and pure autonomic failure with CT, MRI, and PET-FDG. Clin. Auton. Res. 1991;1:27–36
  29. Brooks DJ, Salmon EP, Mathias CJ, et al.  The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain. 1990;113:1539–1552
  30. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 1992;55:181–184
  31. Eidelberg D, Takikawa S, Moeller JR, et al.  Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann. Neurol. 1993;33:518–527
  32. Sawle GV, Playford ED, Burn DJ, et al.  Separating Parkinson's disease from normality: discriminant functional analysis of fluorodopa F18 positron emission tomography data. Arch. Neurol. 1994;51:237–243
  33. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele–Richardson–Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J. Neurol. Neurosurg. Psychiatry. 1994;57:278–284
  34. Brooks DJ, Ibanez V, Sawle GV, et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with [11C] raclopride and positron emission tomography. Ann. Neurol. 1992;31:184–192
  35. Sawle GV, Playford ED, Brooks DJ, et al.  Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naı̈ve parkinsonism. Diagnostic implications of the D2 receptor status. Brain. 1993;116:853–867
  36. Antonini A, Leenders KL, Vontobel P, et al.  Complementary PET studies of strial neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain. 1997;120:2187–2195
  37. Pastakia B, Polinsky RJ, Di Chiro G, et al.  Multiple system atrophy (Shy-Drager syndrome): MR imaging. Radiology. 1986;159:499–502
  38. Savoiardo M, Strada L, Girotti F, et al.  MR imaging in progressive supranuclear palsy and Shy-Drager syndrome. J. Comput. Assist. Tomogr. 1989;13:555–560
  39. Brown RT, Polinsky RJ, Di Chiro G, et al.  MRI in autonomic failure. J. Neurol. Neurosurg. Psychiatry. 1987;50:913–914
  40. Jacques S, Tobes MC, Sisson JC, et al.  Comparison of the sodium dependency of uptake of meta-iodobensylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol. Pharmacol. 1984;26:539–546
  41. Sisson JC, Wieland DM, Sherman P, et al.  Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J. Nucl. Med. 1987;28:1620–1624
  42. Satoh A, Serita T, Tsujihata M. Total defect of metaiodobenzylguanidine imaging on heart in Parkinson's disease: assessment of cardiac sympathetic denervation. Nippon Rinsho. 1979;55:202–206
  43. Yoshita M, Hayashi M, Hirai S. Decreased myocardial accumulation of [123I] metaiodobenzylguanidine in Parkinson's disease. Nucl. Med. Commun. 1998;19:137–142
  44. Braune S, Reinhardt M, Bathmann J, et al.  Impaired cardiac uptake of meta [123I] iodobenzylguanidine in Parkinson's disease and autonomic failure. Acta Neurol. Scand. 1998;97:307–314
  45. Braune S, Reinhardt M, Schnitzer R, et al.  Cardiac uptake of [123I] MIBG separates Parkinson's disease from multiple system atrophy. Neurology. 1999;53:1020–1025
  46. Takatsu H, Nagashima K, Murase M, et al.  Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA. 2000;284:44–45
  47. Goldstein DS, Chang PC, Eisenhofer G, et al.  Positron emission tomograpic imaging of cardiac sympathetic innervation and function. Circulation. 1990;81:1606–1621
  48. Goldstein DS, Holmes C, Cannon RO, et al.  Sympathetic cardioneuropathy in dysautonomias. N. Engl. J. Med. 1997;336:696–702
  49. Schatz IJ, Low PA, Polinsky RJ. Disorders of the autonomic nervous system. N. Engl. J. Med. 1997;337:278–279 [Correspondence]
  50. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992;42:1142–1146
  51. Shannon JR, Jordan J, Costa F, et al.  The hypertension of autonomic failure and its treatment. Hypertension. 1997;30:1062–1067
  52. Muldowney JAS, Biaggioni I, Mosqueda-Garcia F, et al.  Orthostatic heart rate changes in multiple system atrophy. Clin. Auton. Res. 1998;8:269
  53. Wilcox CS, Aminoff MJ, Slater JD. Sodium hemeostasis in patients with autonomic failure. Clin. Sci. Mol. Med. 1977;53:321–328
  54. Davidson C, Smith D, Morgan DB. Diurnal pattern of water and electrolyte excretion and body weight in idiopathic orthostatic hypotension. The effect of three treatments. Am. J. Med. 1976;61:709–715
  55. Biaggioni I, Onrot J, Stewart CK, Robertson D. The potent pressor effect of phenylpropanolamine in patients with impairment. JAMA. 1987;258:236–239
  56. Chobanian AV, Volicer L, Tifft CP, et al.  Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N. Engl. J. Med. 1979;301:68–73
  57. Bickelman AG, Lippschutz EJ, Brunjes CF. Hemodynamics of idiopathic orthostatic hypotension. Am. J. Med. 1961;30:26–38
  58. Ibrahim MM, Tarazi RC, Dustan HP, Bravo EL. Idiopathic orthostatic hypotension: circulatory dynamics in chronic autonomic insufficiency. Am. J. Cardiol. 1974;34:288–294
  59. Kronenberg MW, Forman MB, Onrot J, Robertson D. Enhanced left ventricular contractility in autonomic failure: assessment using pressure-volume relations. J. Am. Coll. Cardiol. 1990;15:1334–1342
  60. Biaggioni I, Garcia F, Inagami T, Haile V. Hyporeninemic normoaldosteronism in severe autonomic failure. J. Clin. Endocrinol. Metab. 1993;76:580–586
  61. Michelakis AM, Robertson D. Plasma renin activity and levodopa in Parkinson's disease. JAMA. 1970;213:83–85
  62. Jordan J, Shannon JR, Black BK, et al.  NN-nicotinic blockade as an acute human model of autonomic failure. Hypertension. 1998;31:1178–1184
  63. Gordon RD, Kuchel O, Liddle GW, Island DP. Role of the sympathetic nervous system in regulating renin and aldosterone production in man. J. Clin. Invest. 1967;46:599–605
  64. Robertson D, Goldberg MR, Tung CS, et al.  Use of alpha 2 adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic nervous system. J. Clin. Invest. 1986;78:576–581
  65. Shannon JR, Jordan J, Diedrich A, et al.  Sympathetically mediated hypertension in autonomic failure. Circulation. 2000;101:2710–2715
  66. Shannon JR, Jordan J, Black BK, et al.  Uncoupling of the baroreflex by NN-cholinergic blockade in dissecting the components of cardiovascular regulation. Hypertension. 1998;32:101–107
  67. Biaggioni I, Robertson RM, Robertson D. Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J. Clin. Pharmacol. 1994;34:418–423
  68. Goldstein DS, Polinsky RJ, Garty M, et al.  Patterns of plasma catechols in neurogenic orthostatic hypotension. Ann. Neurol. 1989;26:558–563
  69. Robertson D, Goldberg MR, Hollister AS, et al.  Clonidine raises blood pressure in severe orthostatic hypotension. Am. J. Med. 1983;74:193–200
  70. Fahmy NR, Soter NA. Effects of trimethaphan on arterial blood histamine and systemic hemodynamics in humans. Anesthesiology. 1985;62:562–566
  71. Harioka T, Hatano Y, Mori K, Toda N. Trimethaphan is a direct vasodilator and an alpha-adrenoreceptor antagonist. Anesth. Analg. 1984;63:290–296
  72. Baylis PH, Robertson GL. Osmotic and non-osmotic stimulation of vasopressin release. [proceedings] J. Endocrinol. 1979;83:39P–49P
  73. Kaufmann H, Oribe E, Miller M, et al.  Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology. 1992;42:590–593
  74. Bussien JP, Waeber B, Nussberger J, et al.  Does vasopressin sustain blood pressure of normally hydrated healthy volunteers?. Am. J. Physiol. 1984;246:H143–H147
  75. Cowley AW, Monos E, Guyton AC. Interaction of vasopressin and the baroreceptor reflex in the regulation of arterial blood pressure in the dog. Circ. Res. 1974;34:505–514
  76. Mohring J, Glanzer K, Maciel JA, et al.  Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J. Cardiovac. Pharmacol. 1980;2:367–376
  77. Houck OC, Fiksen-Olsen MJ, Britton BL, Romero JC. Role of angiotensin and vasopressin on blood pressure of ganglionic blocked dogs. Am. J. Physiol. 1983;244:H115–H120
  78. Gavras I, Hatinoglou S, Gavras H. The adrenergic system and the release and pressor action of vasopressin. Hypertension. 1986;8(suppl. II):II-163–II-167
  79. Klein C, Brown R, Wenning G, Quinn N. The “cold hands sign” in multiple system atrophy. Mov. Disord. 1997;12:514–518
  80. McTavish D, Goa KL. Midodrine: a review of its pharmacologic properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs. 1989;38:757–777
  81. Jankovic J, Gilden JL, Hiner BC, et al.  Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am. J. Med. 1993;95:38–48
  82. Chobanian AV, Volicer L, Tifft CP, et al.  Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N. Engl. J. Med. 1979;301:68–73
  83. Zerbe RL, Henry DP, Robertson GL. Vasopressin response to orthostatic hypotension. Etiologic and clinical implications. Am. J. Med. 1983;74:265–271
  84. Mathias CJ, Fosbraey P, da Costa DF, et al.  The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br. Med. J. (Clin. Res. Ed.). 1986;293:353–354
  85. Sato T, Kawada T, Shishido T, et al.  Novel therapeutic strategy against central baroreflex failure: a bionic baroreflex system. Circulation. 1999;100:299–304
  86. Gilman S, Low PA, Quinn N, et al.  Consensus statement on the diagnosis of multiple system atrophy. J. Auton. Nerv. Syst. 1998;74:189–192

PII: S0022-510X(02)00126-0

Journal of the Neurological Sciences
Volume 200, Issue 1 , Pages 1-10 , 15 August 2002

Article Tools